HUMA Earnings & Financial Statements
Humacyte, Inc.
$0.35
-$0.00(-1.34%)
35
Overall
40
Value
36
Tech
31
Quality
Market Cap
$98.37M
Volume
5.41M
52W Range
$0.39 - $1.90
Target Price
$1.63
HUMA earnings and financial statements: Humacyte, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
HUMA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.04M | - | - | $1.56M | $1.26M |
| Cost of revenue | $9.70M | - | - | - | - |
| Operating income | -$108.14M | -$114.40M | -$100.00M | -$84.60M | -$81.20M |
| EBITDA | -$22.19M | -$132.18M | -$102.88M | $2.44M | -$13.89M |
| Net income | -$40.83M | -$148.70M | -$110.78M | -$11.96M | -$26.48M |
| EPS (diluted) | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $116.37M | $137.87M | $128.22M | $204.30M | $286.53M |
| Total liabilities | $113.26M | $190.54M | $114.68M | $87.37M | $164.36M |
| Shareholders’ equity | $3.11M | -$52.67M | $13.55M | $116.93M | $122.17M |
| Cash and equivalents | $50.50M | $44.94M | $80.45M | $149.77M | $217.50M |
| Long-term debt | $62.42M | $13.62M | $54.89M | $39.19M | $49.15M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$105.04M | -$98.12M | -$73.31M | -$71.13M | -$81.19M |
| Capital expenditure | -$884.0K | -$1.57M | -$2.28M | -$1.05M | -$220.0K |
| Free cash flow | -$105.93M | -$99.69M | -$75.58M | -$72.18M | -$81.41M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HUMA | $0.35 | -1.3% | 5.41M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |